TRPV1 inhibition suppresses non-small cell lung cancer progression by inhibiting tumour growth and enhancing the immune response
ConclusionOur study suggests that TRPV1 acts as a tumour promoter in NSCLC, mediating pro-proliferative and anti-apoptotic effects on NSCLC through IGF1R signaling and regulating GABA release to affect the tumour immune response. (Source: Cellular Oncology)
Source: Cellular Oncology - October 30, 2023 Category: Cancer & Oncology Source Type: research
Retraction Note: IFIT1 modulates the proliferation, migration and invasion of pancreatic cancer cells via Wnt/ β-catenin signaling
(Source: Cellular Oncology)
Source: Cellular Oncology - October 30, 2023 Category: Cancer & Oncology Source Type: research
The microbiota and renal cell carcinoma
AbstractRenal cell carcinoma (RCC) accounts for about 2% of cancer diagnoses and deaths worldwide. Recent studies emphasized the critical involvement of microbial populations in RCC from oncogenesis, tumor growth, and response to anticancer therapy. Microorganisms have been shown to be involved in various renal physiological and pathological processes by influencing the immune system function, metabolism of the host and pharmaceutical reactions. These findings have extended our understanding and provided more possibilities for the diagnostic or therapeutic development of microbiota, which could function as screening, progn...
Source: Cellular Oncology - October 25, 2023 Category: Cancer & Oncology Source Type: research
Inhibition of thioredoxin-1 enhances the toxicity of glycolysis inhibitor 2-deoxyglucose by downregulating SLC1A5 expression in colorectal cancer cells
ConclusionOur results demonstrate a novel adaptive mechanism of glycolytic inhibition in which Trx-1 increases GSH levels by regulating SLC1A5 to rescue cytotoxicity induced by 2DG in CRC cells. Inhibition of glycolysis in combination with inhibition of Trx-1 or SLC1A5 may be a promising strategy for the treatment of CRC. (Source: Cellular Oncology)
Source: Cellular Oncology - October 23, 2023 Category: Cancer & Oncology Source Type: research
FAP is a prognostic marker, but not a viable therapeutic target for clinical translation in HNSCC
ConclusionAlthough FAP+ CAFs have attracted increasing attention for their role in cancer, the feasibility and efficacy of FAP-targeting therapies for HNSCC remain doubtful. (Source: Cellular Oncology)
Source: Cellular Oncology - October 19, 2023 Category: Cancer & Oncology Source Type: research
High-plex spatial transcriptomic profiling reveals distinct immune components and the HLA class I/DNMT3A/CD8 modulatory axis in mismatch repair-deficient endometrial cancer
ConclusionOur study confirmed the heterogeneous TME status within MMRd-ECs and showed that these ECs can be stratified based on potential biomarkers such as HLA class I, DNMT3A and CD8 in pathological settings for improved ICI therapeutic efficacy in this subset of patients. (Source: Cellular Oncology)
Source: Cellular Oncology - October 17, 2023 Category: Cancer & Oncology Source Type: research
Hepatitis B virus core protein stabilizes RANGAP1 to upregulate KDM2A and facilitate hepatocarcinogenesis
ConclusionsThese findings demonstrate a novel mechanism by which HBC facilitates hepatocarcinogenesis. RANGAP1 and KDM2A could act as potential molecular targets for treating HBV-associated malignancy. (Source: Cellular Oncology)
Source: Cellular Oncology - October 17, 2023 Category: Cancer & Oncology Source Type: research
Correction: Targeting ARHGEF12 promotes neuroblastoma differentiation, MYCN degradation, and reduces tumorigenicity
(Source: Cellular Oncology)
Source: Cellular Oncology - October 16, 2023 Category: Cancer & Oncology Source Type: research
Identifying cancer subtypes based on embryonic and hematopoietic stem cell signatures in pan-cancer
ConclusionOur findings indicate that the ESC signature is an adverse prognostic factor in cancer, while the HSC signature and ratio of HSC/ESC signatures are positive prognostic factors. The subtyping of cancer based on ESC and HSC signatures may provide insights into cancer biology and clinical implications of cancer. (Source: Cellular Oncology)
Source: Cellular Oncology - October 12, 2023 Category: Cancer & Oncology Source Type: research
Feature-weight based measurement of cancerous transcriptome using cohort-wide and sample-specific information
AbstractIdentifying cancerous samples or cells using transcriptomic data is critical for cancer related basic research, early diagnosis, and targeted therapy. However, the high transcriptional heterogeneity of cancers still hinders people from accurately recognizing cancerous transcriptome using bulk, single-cell, or spatial RNA-seq data. Here, we present a novel method named FWP (Feature Weight Pro) that helps measure cancerous transcriptome using transcriptomic data. The workflow of FWP is, first, to calculate feature weights using the training dataset, and then, for each sample in the testing dataset, calculate the feat...
Source: Cellular Oncology - October 9, 2023 Category: Cancer & Oncology Source Type: research
Plasma cell signatures predict prognosis and treatment efficacy for lung adenocarcinoma
Conclusion: We proposed a prediction mode which can effectively identify high-risk LUAD patients and found three novel genes closely correlated with PC tumor infiltration. (Source: Cellular Oncology)
Source: Cellular Oncology - October 9, 2023 Category: Cancer & Oncology Source Type: research
Redox signaling-mediated tumor extracellular matrix remodeling: pleiotropic regulatory mechanisms
ConclusionsThe redox-mediated ECM remodeling contributes importantly to tumor survival, progression, metastasis, and poor prognosis. A comprehensive investigation of the concrete mechanism of redox-mediated tumor ECM remodeling and the combination usage of redox-targeted drugs with existing treatment means may reveal new therapeutic strategy for future antitumor therapies. (Source: Cellular Oncology)
Source: Cellular Oncology - October 4, 2023 Category: Cancer & Oncology Source Type: research
Neuropilin-2 acts a critical determinant for epithelial-to-mesenchymal transition and aggressive behaviors of human head and neck cancer
ConclusionsThese findings suggest that NRP2 is a critical determinant in provoking EMT and aggressive behaviors in human HNC through the RSK1/Sox2/Zeb1 axis, and MECF may have the potential to be a novel NRP2 inhibitor for treating metastasis in HNC patients. (Source: Cellular Oncology)
Source: Cellular Oncology - October 3, 2023 Category: Cancer & Oncology Source Type: research
FGF19 promotes nasopharyngeal carcinoma progression by inducing angiogenesis via inhibiting TRIM21-mediated ANXA2 ubiquitination
ConclusionFGF19 promoted NPC angiogenesis by inhibiting TRIM21-mediated ANXA2 ubiquitination. It may serve as a noninvasive biomarker for NPC and provides new insights for therapy. (Source: Cellular Oncology)
Source: Cellular Oncology - October 2, 2023 Category: Cancer & Oncology Source Type: research
MAOA suppresses the growth of gastric cancer by interacting with NDRG1 and regulating the Warburg effect through the PI3K/AKT/mTOR pathway
ConclusionsMAOA attenuated glycolysis and inhibited the progression of gastric cancer through the PI3K/Akt/mTOR pathway. Loss of function or downregulation of MAOA can facilitate gastric cancer progression. Overexpression of MAOA and inhibition of the PI3K/Akt/mTOR pathway may provide a potential method for gastric cancer treatment in clinical therapeutic regimens. (Source: Cellular Oncology)
Source: Cellular Oncology - October 1, 2023 Category: Cancer & Oncology Source Type: research
